{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=107", "query": { "condition": "Lymphoma", "page": 107 }, "page_size": 10 }, "pagination": { "page": 107, "page_size": 10, "total_count": 5760, "total_pages": 576, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=108&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=106&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T16:30:12.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00520637", "title": "A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "EZN-2208", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enzon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-10-09", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520637" }, { "nct_id": "NCT02689453", "title": "Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Lymphoma Relapsed", "Adult T-Cell Leukemia (ATL)", "Peripheral T-Cell Lymphoma (PTCL)", "Cutaneous T Cell Lymphoma (CTCL)", "T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "IL-15 plus", "type": "BIOLOGICAL" }, { "name": "alemtuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-01-19", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02689453" }, { "nct_id": "NCT04439253", "title": "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-08-12", "completion_date": "2027-03-17", "has_results": true, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439253" }, { "nct_id": "NCT00060645", "title": "Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2003-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2015-08-27", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060645" }, { "nct_id": "NCT02228772", "title": "Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "B-cell Adult Acute Lymphoblastic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "MLN 9708", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "51 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "51 Years to 75 Years" }, "enrollment_count": 19, "start_date": "2014-12", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228772" }, { "nct_id": "NCT03734601", "title": "Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Disorder", "Chronic Lymphocytic Leukemia", "B-cell Lymphoma", "T-cell Lymphoma", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Total body irradiation (TBI)", "type": "RADIATION" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Total lymphoid irradiation (TLI)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-11-05", "completion_date": "2020-11-17", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734601" }, { "nct_id": "NCT01625351", "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Gastrointestinal Tumor", "Germ Cell Tumor", "Hepatic Tumor", "Lymphoma", "Wilms Tumor", "Rhabdoid Tumor", "Clear Cell Carcinoma", "Renal Cell Carcinoma", "Melanoma", "Neuroblastoma", "Rhabdomyosarcoma", "Non-rhabdomyosarcoma" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "stem cells", "type": "BIOLOGICAL" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 23, "start_date": "2012-08-20", "completion_date": "2020-02-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625351" }, { "nct_id": "NCT00797472", "title": "Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin's Disease" ], "interventions": [ { "name": "R-mabHD", "type": "DRUG" }, { "name": "ABVD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Scitech International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 120, "start_date": "2011-07", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2011-07-20", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "Englishtown, New Jersey", "locations": [ { "city": "Englishtown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00797472" }, { "nct_id": "NCT04038359", "title": "A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SecuraBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2019-09-24", "completion_date": "2023-07-24", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 6, "location_summary": "Fort Myers, Florida • Lecanto, Florida • Orange City, Florida + 3 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Lecanto", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04038359" }, { "nct_id": "NCT01228461", "title": "Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fatigue", "Hodgkin Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "15 Years to 39 Years" }, "enrollment_count": 10, "start_date": "2010-02", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-11-06T16:30:12.423Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01228461" } ] }